[General schema for safety evaluation of residues of embryotoxic drugs (author's transl)].
Concerned with adapting the withdrawal time to real risks attributed to residues, the authors present a general schema of evaluation based on the metabolism-toxicity relationship. This schema takes into account: a) possible distinction between potentially toxic and atoxic metabolites for extractable residues, b) the more or less large biovailability of residues, c) the methodological evaluation difficulties of toxicity of bound residues. Without neglecting public health, this procedure leads to less constrained restrictions in use of veterinary drugs.
D000014:Abnormalities, Drug-Induced; D000818:Animals; D001562:Benzimidazoles / Q000378:metabolism / Q000633:toxicity; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D004357:Drug Synergism; D064420:Drug-Related Side Effects and Adverse Reactions; D004622:Embryo, Mammalian / Q000187:drug effects*; D005260:Female; D006801:Humans; D011247:Pregnancy; D011634:Public Health; D011817:Rabbits; D051381:Rats; D012306:Risk; D014730:Veterinary Medicine
D001562:Benzimidazoles
Schéma général d'évaluation de la sécurité des résidus de médicaments embryotoxiques.